Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
All News
Article
A new hand-held scanner developed by UCL researchers can generate highly detailed 3D photoacoustic images in just seconds, paving the way for their use in a clinical setting for the first time and offering the potential for earlier disease diagnosis.
Article
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
Article
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.
Article
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Article
Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.
Article
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody product normally used in multiple myeloma.
Article
Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.
Dr. John Cush
Tweet
Full read review of Pathogenic autoantibodies in idiopathic inflammatory myopathies: antisynthetase autoAbs, TIF1, MDA5, SRP, HMGCR, TRIM72, cN1A, FHL1, eIF3 autoantibodies and more https://t.co/uzCmauulWZ https://t.co/twhwCB4xof
Dr. John Cush
Tweet
Study of oral microbiota & psoriasis (72 PSO vs 16 healthy controls) - 16S rRNA gene sequencing of saliva found (in PSO) signif incrCapnocytandophaga, Campylobacter, Acetobacter, but decr Bacteroides, Muribaculaceae. PSA pts incr Aggregatibacter, but decr Prevotella… https://t.co/GukbWkl1Gz https://t.co/HgLcD6bP2I
Dr. John Cush
Tweet
Trends in Early Undifferentiated PolyArthritis presentation. Over 3 eras (1998-2004-245 pts; 2005-10 266 pts; 2011-22 329 pts) many Sxs & Rx same. But Sxs duration 2.9 to 4.1mos, seropositivity 54 to 42%, Erosion score 18 to 9, mostly in Seroneg pts; Steroids incr 18 to 33%… https://t.co/AZfjqB4xGI https://t.co/GEwDWjccxl
Dr. John Cush
Tweet
TUDOR study looked at the incidence of PsA by serially following primary care psoriasis pts. At 1 year, 14/511 developed PsA (incidence 2.74 per 100 p-yrs) and at 2 years 7/444 developed PsA (1.58/100 p-yrs). Combined incidence @2 yrs - 2.2 per 100 p-yrs https://t.co/pbHBWt0pXn https://t.co/tHMhQs1cqN
Dr. John Cush
Tweet
TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein… https://t.co/1NYgYtYKIr https://t.co/fMMy2DzSxN
Dr. John Cush
Tweet
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/4fgkNJeO4i https://t.co/Z2lDloBzrI
Dr. John Cush
Tweet
Increasing Incidence of Morphea
A large EMR cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on the increasing prevalence of morphea.
https://t.co/ISqv4y0Pkp https://t.co/KM3gbt2iWd
Dr. John Cush
Tweet
Exploratory analysis from an academic center showed SLE pts w/ higher odds of positive ANA vs. other ANA-asso diseases (OR 2.10). Over 20 yrs, ANA titers are more dynamic than expected; & average titers being higher in early disease and decreasing over time.… https://t.co/iQXN0nPSIG https://t.co/viMTGen34K
Dr. John Cush
Tweet
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE https://t.co/3oN5qUHpUU
Dr. John Cush
Tweet
Study of 4370 RA pts (26534 PYs) saw 362 MACE (CV) events. RA activity & inflammatory markers assoc w/ MACE risk in bDMARD non-users (not those on bDMARDs). 515 bDMARD vs 3855 non-users (n=3855). Each DAS28-CRP unit incr MACE risk (HR 1.21)https://t.co/lRaHxTHzqe https://t.co/usEiJctVYk
